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ABSTRACT
Objective To assess whether vaccination against human
papillomavirus (HPV) increases the risk of miscarriage.
Design Pooled analysis of two multicentre, phase three
masked randomised controlled trials
SettingMulticentre trials in several continents and in
Costa Rica.
Participants 26130 women aged 15-25 at enrolment;
3599 pregnancies eligible for analysis.
Interventions Participants were randomly assigned to
receive three doses of bivalent HPV 16/18 VLP vaccine
with AS04 adjuvant (n=13075) or hepatitis A vaccine as
control (n=13055) over six months.
Main outcome measuresMiscarriage and other
pregnancy outcomes.
Results The estimated rate of miscarriage was 11.5% in
pregnancies in women in the HPV arm and 10.2% in the
control arm. The one sided P value for the primary analysis
was 0.16; thus, overall, there was no significant increase
inmiscarriage amongwomenassigned to theHPV vaccine
arm. In secondary descriptive analyses, miscarriage rates
were 14.7% in the HPV vaccine arm and 9.1% in the
control arm in pregnancies that began within three
months after nearest vaccination.
Conclusion There is no evidence overall for an association
between HPV vaccination and risk of miscarriage.
Trial registration Clinical Trials NCT00128661 and
NCT00122681.
INTRODUCTION
Human papillomaviruses (HPV) cause virtually all of
the nearly half million incident cases and quarter mil-
lion deaths each year from cancer of the cervix.1 2 Ran-
domised trials have shown that two vaccines based on
an antigen consisting ofHPVL1 protein virus-like par-
ticles are highly efficacious at preventing end points
that are part of the natural course of cervical
cancer.3-5 The Gardasil vaccine targets HPV types 16
and18,which cause 70%of cervical cancer, and types 6
and 11, which cause genital warts. The Cervarix vac-
cine targets types 16 and 18. Both vaccines are licensed
in Europe, the United States, and many countries
around the world.
Because one main target population of the vaccines
is women of reproductive age, ameaningful increase in
risk of serious adverse effects on reproduction would
mitigate some of the public health benefit of reduced
morbidity and mortality during adulthood because of
lower rates of cervical cancer and its precursors. Mis-
carriage is themost prevalent adverse outcomeof preg-
nancy. Although vaccines are not known to affect the
risk of miscarriage,6 Cervarix’s new AS04 adjuvant
could, in theory, cause alterations inmaternal immune
function in early pregnancy.7 The magnitude of any
increased risk of miscarriage and of the set of pregnan-
cies at increased riskwould be important factors in per-
sonal decisions and public health policy on use of the
HPV vaccines. Furthermore, any increase in the base-
line rate of miscarriage because of the vaccine would
raise concern that it might have other unrecognised
biological activity. On the other hand, receipt of a vac-
cine with no effect on miscarriage might lower a
woman’s lifetime risk of preterm delivery and inferti-
lity by reducing the need for cone excision for treat-
ment of precancerous lesions related to HPV.8
We determined the risk of miscarriage in two inde-
pendent phase three double blind randomised con-
trolled efficacy trials of Cervarix. In a combined
analysis, we compared the risk of miscarriage in preg-
nancies conceived after vaccination with Cervarix or
with a hepatitis A vaccine as control. Because the
mechanisms by which the vaccine could affect preg-
nancies are unknown, we also do not know the specific
time at risk between conception and vaccination.
Therefore, we use a statistical test in our primary ana-
lysis that maintains statistical power when the vaccine
does have an effect, regardless of the true subset of
pregnancies at increased risk, with rigorous control of
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the chance of falsely reporting a positive conclusion
when the vaccine has no effect.
METHODS
Trials of Cervarix
We included data collected in double blinded rando-
mised clinical trials to evaluate the efficacy of Cervarix
for prevention of cervical lesions and persistent infec-
tion with HPV types 16 and 18 from two independent
large studies. PApillomaTRIal againstCancer Inyoung
Adults (PATRICIA)3 is amulticentre trial sponsored by
GlaxoSmithKline Biologicals (GSK). The Costa Rica
VaccineTrial (CVT)9 is a study inCostaRica sponsored
by the National Cancer Institute (NCI).
Origin of this report
After the planned interim analysis of PATRICIA
showed imbalance in the miscarriage rates between
the two arms, the data safety monitoring board of
CVT asked the trial statistician (SW) to prepare a
report on miscarriage based on data in both trials.
With the help of two outside consultants (AJW and
GM), the trial statistician presented a plan to the
board, acquired the required data from the indepen-
dent statistician for PATRICIA (Lieven Declerck, S-
Clinica, Brussels, Belgium), and prepared an analysis.
The results were presented separately to the data safety
monitoring board for CVT and the independent data
monitoring committee for PATRICIA. Members of
the twoboards asked the statistician to prepare amanu-
script for publication. The GSK Biological researchers
had opportunities to ask questions and to comment on
the research plan, results, and manuscripts, but the
CVT statistician and the outside consultants prepared
reports for themonitoring boards and, with the named
authors, prepared this manuscript independently.
Participants in the analysis
Eligible women between ages 15 (PATRICIA) or 18
(CVT) and 25 consented to take part and were rando-
mised to receive three doses of vaccine, at baseline and
at one and six months. Women received either the
HPV 16/18 vaccine formulated with the AS04 adju-
vant system or a control hepatitis A vaccine consisting
of 720 ELISA units of inactivated viral antigen with
Alum, formulated in 0.5ml doses. Eachwoman under-
went a pregnancy test on a urine sample before each
vaccination; vaccination was discontinued when the
result was positive. Enrolled women with childbearing
potential agreed to use birth control from one month
before the first vaccination until two months after the
last vaccination, per study protocol. Women are being
followed at least annually for a period of four years
from first vaccination.
Figure 1 shows follow-up through the data freeze
points of 31 January2008 (PATRICIA) and20Decem-
ber 2007 (CVT) among the 26 130 women and 2567
reported pregnancies included in this analysis. Addi-
tional details on the two studies are available
elsewhere.3 9
Collection of information on pregnancy
Both studies actively monitored participants’ safety,
including information on pregnancies and their out-
comes throughout the entire studyperiod. Specifically,
immediately after learning that a woman was preg-
nant, study staff completed a form documenting the
expected delivery date based on report of her lastmen-
strual period. They also contacted the woman after her
expected delivery date to learn the pregnancy out-
come. Staff coded information on gynaecological his-
tory, date of last menstrual period, date of end of
pregnancy, gestational age, whether the delivery was
vaginal or caesarean, and delivery outcome and
weight, length, sex, Apgar score, and outcome of the
baby. Women were instructed to report serious
adverse events related to pregnancies at any time dur-
ing follow-up.Any reported abnormality of pregnancy
or delivery and any medical condition of the baby at
birth were documented with appropriate forms and
reported according to the local regulations and the
good clinical practice guidelines. All adverse events
were coded withMEDRApreferred codes for PATRI-
CIA and with the Spanish edition of ICD-10 (inter-
national classification of diseases, 10th revision) for
CVT. The date of the last menstrual period was
abstracted from charts or inferred from information
supplied by the woman. We calculated the estimated
date of conception as 14 days after the last period. We
defined miscarriage as loss of pregnancy within
20weeks after the last period. Diagnosis ofmiscarriage
was by self report and clinical judgment of the investi-
gator; a positive pregnancy test result followed by a
negative result was usually considered to be loss of
Hepatitis A vaccine (n=13 075)HPV vaccine (n=13 055)
Women randomised (n=26 130) (49 174 person years of follow-up)
Intrauterine pregnancies (n=2364)Intrauterine pregnancies (n=2346)
Pregnancies included in analysis (n=1786;
1594 women had one pregnancy, 95 had ≥2)
Pregnancies included in analysis (n=1813;
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Pregnancies excluded (n=12):
  Ectopic (n=10)
  Molar (n=2)
Pregnancies excluded (n=19):
  Ectopic (n=15)
  Molar (n=4)
W
om
en
Pr
eg
na
nc
ie
s
Excluded (n=560):
  Recent pregnancy (n=508)
  Missing date of last menstrual
    period (n=52)
Excluded (n=551):
  Recent pregnancy (n=489)
  Missing date of last menstrual
    period (n=62)
Fig 1 | Follow-up through data freeze points (20 Dec 2007 for CVT and 31 Jan 2008 for PATRICIA)
for women and pregnancies leading to 373 miscarriages. In CVT three women received wrong
vaccination (one in HPV group and two in hepatitis A group) and were classified according to
intention to treat; one woman randomised twice was excluded. Recent pregnancies were
defined as those that began within one year of data freeze point
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pregnancy. We excluded six molar and 25 ectopic
pregnancies from all analyses because their causes
are likely to be different from most miscarriages. We
collected data on induced abortions only in those
countries where they are legal. (See appendix 1 on
bmj.com for further details on collection of data relat-
ing to pregnancy.)
Statistical analysis
Ongoing pregnancies and induced abortions—To reduce
the number of ongoing pregnancies in the analysis,
which would require additional statistical assump-
tions, we excluded all pregnancies with estimated con-
ception dates less than one year before the data lock
point; for pregnancies included in the analysis, we
included all information available at the time of ana-
lysis. Each woman received one to three doses of vac-
cine. We calculated the days between dates of each
vaccination and dates of estimated conception; we
used dates of first vaccination dose, most recent vacci-
nation dose before the estimated conception date, and
vaccination dose nearest to (whether before or after)
the estimated conception dates as three different ori-
gins of time scales. For miscarriage analyses we exam-
ined the effect of vaccination in subsets of pregnancies
defined by time between conception and nearest vac-
cination. We also analysed the chance of any preg-
nancy and pregnancy ending in live birth by time
after first vaccination.
Rates of miscarriage—We used the ratio of pregnancy
losses before 20 weeks’ gestational age to total pregnan-
cies,with a correction for pregnancies and induced abor-
tions thatmighthave ended inmiscarriage (see appendix
2 on bmj.com), as the definition of the rate of miscar-
riage. We calculated rates of miscarriage for subsets of
pregnancies defined by time between vaccination and
conception. We present graphs showing risk of miscar-
riage by arm and the difference between them for preg-
nancies conceived at various times since vaccination.
The pattern of arm specific rates by time between vacci-
nation and conceptionmight help to distinguishwhether
a difference is caused by a higher rate in the HPV vac-
cine arm or a reduced rate in the control arm.
Permutation test to address lack of knowledge of time of
conception during which vaccination might confer risk—A
standard test of the effect of vaccination on risk of mis-
carriage requires specification of the timing of preg-
nancies that might be affected by vaccination—for
example, the vaccine might affect only those pregnan-
cies with a conception date within eight weeks of the
vaccination date. Specifying the wrong set of pregnan-
cies for analysis can reduce power substantially com-
pared with an analysis based on the correctly specified
set of pregnancies. Our test statistic, therefore, is the
lowest P value among several tests of the same hypoth-
esis in overlapping subsets of pregnancies defined by
time between vaccination and conception. Our null
hypothesis was that the vaccine confers no additional
risk of miscarriage for pregnancies conceived at any
time before or after vaccination. The alternative
hypothesis is that the vaccine confers additional risk
of miscarriage for a subset of pregnancies defined by
time between vaccination and conception. We used a
permutation test, sometimes called a randomisation
test, to obtain the distribution of the test statistic
under the null hypothesis. Tests use one sided P values
because a lower miscarriage rate in the Cervarix arm
would not be a safety concern. A P value of 0.025 is the
standard for significance. This procedure has
Table 1 | Pregnancy outcomes in pooled data from 26 130 women in two trials of vaccine
against human papillomavirus (HPV) types 16 and 18 (with hepatitis A vaccine as control).
Figures are numbers (percentages)
HPV vaccine Hepatitis A vaccine Total
Miscarriages 197 (11.0) 176 (9.7) 373 (10.4)
Gestation at miscarriage (weeks):
0-6 43 38 81
7-12 108 107 215
13-20 44 30 74
Induced abortions* 127 (7.1) 128 (7.1) 255 (7.1)
Stillbirths 15 (0.8) 13 (0.7) 28 (0.8)
Live births 1401 (78.4) 1449 (79.9) 2850 (79.2)
Gestation at live birth (weeks):
≤33 30 41 71
34-36 75 83 158
≥37 1295 1325 2620
Ongoing pregnancies 46 (2.6) 47 (2.6) 93 (2.6)
Gestation at last contact in ongoing pregnancies (weeks):
≤20 15 24 39
>20 31 23 54
Total pregnancies 1786 1813 3599
*Information on induced abortion collected only in those countries where it is legal.
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Fig 2 | Miscarriage rates for both arms and differences according to time between nearest
vaccination and estimated date of conception. Of 3599 pregnancies included in analysis, 187
(5.2%) had estimated conception date before nearest vaccination. Estimations of conception
assume that ovulation occurs on day 14 after last menstrual period, though 10% of cycles
have ovulation at day 24 or later.13 Among 187 pregnancies with conception ostensibly before
vaccination, many had conception dates only a few days before vaccination (median 10 days).
Given that all pregnant women had negative hCG test results at time of vaccination (based on
highly sensitive β hCG assays), most subsequent pregnancies had probably been conceived
after relatively late ovulations and conception had occurred after vaccination. Thus, these data
do not provide useful data on the question of vaccine safety before conception (HAV=hepatitis
A vaccine)
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reasonable power for a wide range of pregnancy sub-
sets thatmight be at increased risk ofmiscarriage, albeit
with less power than the standard test with the subset at
increased risk specified correctly (see supplemental
tables 1a-1e in appendix 6 on bmj.com). (Further
details about the permutation test and the power of
permutation and standard tests for alternative hypoth-
eses are in appendices 3 and 4 on bmj.com.)
Subgroup and sensitivity analyses—We conducted sub-
group analyses thought a priori to have possible impor-
tance by applying the permutation method separately
for PATRICIA and CVT; maternal age at estimated
conception date of ≤20, 21-23, and ≥24 years; pregnan-
cies that came to the attention of investigators within
eight weeks and more than eight weeks after the last
menstrual period; and the number of vaccinations
received by the participant before the estimated date
of conception of the pregnancy. We also applied the
permutation test on subsets of pregnancy defined by
time between vaccination and estimated conception
and on subsets of miscarriages defined by gestational
age. Because the pregnancy, not the woman, is the unit
of observation, we checked whether smoking, parity,
age at enrolment, or age at conception was associated
with the assigned group. As no evidence of association
was seen (data not shown) we did not perform an ana-
lysis adjusting for covariates.
Total pregnancies and live births—We compared the
rates of total pregnancy and of live births by time
between first vaccination and possible date of concep-
tion. Further details about themethods for comparison
of rates of total pregnancy and live birth are in appen-
dix 5 on bmj.com.
RESULTS
Therewere 4710 pregnancieswith an estimated date of
conception after enrolment among 26 130 randomised
women. We excluded 25 ectopic and six molar preg-
nancies; 19 of these 31 (61%) were in the HPV vaccine
arm. We excluded 997 pregnancies with estimated
date of conception less than one year from the data
freeze date (including 76 (7.6%) miscarriages and 3
(0.3%) stillbirths) and 114 pregnancies with missing
date of last menstrual period (among which there
were 14 (12%) miscarriages and 2 (2%) stillbirths). Of
the remaining 3599 intrauterine pregnancies, 2850
Table 2 | Overall and subgroup analyses of pregnancy outcome* by permutation tests of whether rate of miscarriage in HPV
vaccine arm is greater than in hepatitis A vaccine arm
Category and
subgroup
HPV vaccine Hepatitis A vaccine
P value (one sided)†No of pregnancies Miscarriage rate (%) No of pregnancies Miscarriage rate (%)
All pregnancies 1708.5 11.5 1727 10.2 0.16
Subset of pregnancies
Study:
PATRICIA 972.5 10.6 990 9.0 0.12
CVT 736 12.8 737 11.8 0.69
Maternal age at conception (years):
≤20 519.5 9.4 531 9.8 0.77
21-23 561.5 11.6 602.5 11.1 0.26
≥24 627.5 13.2 593.5 9.6 0.17
Gestational age at which pregnancy was reported (weeks after estimated conception):
<8 513.5 16.9 569.5 12.3 0.13
≥8 1192 9.2 1153.5 9.1 0.19
No of vaccinations before estimated time of conception:
1 154 11.0 142.5 11.2 0.52
2 381.5 13.4 370.5 11.3 0.28
3 1132 11.0 1181.5 9.6 0.44
Interval between estimated date of conception and nearest vaccination (days):
<90 488 13.7 456.5 9.2 0.033
90‡ 394 14.7 373.5 9.1 0.031
≥90 1220.5 10.7 1270.5 10.5 0.68
Subset of miscarriages§
Gestation at miscarriage (weeks):
0-6 1708.5 2.5 1727 2.2 0.59
7-12 1708.5 6.3 1727 6.2 0.12
13-20 1708.5 2.6 1727 1.7 0.13
PATRICIA=papilloma trial against cancer in young adults; CVT=Costa Rica vaccine trial.
*Induced abortions counted as half pregnancy in columns of counts and in denominator of rates.
†Permutation test statistic is minimum P value for difference in rates for all pregnancies conceived during selected windows of time between
vaccination and estimated date of conception (EDC). By restricting pregnancies considered in permutation test, we reduced number of intervals
considered and focused on those most likely to be at risk if vaccine has effect.
‡Estimated date of conception on or after date of vaccination but less than 90 days after nearest vaccination.
§Rates are percentages of all pregnancies with miscarriage in specified interval of gestational age.
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(79.2%) ended in live births (table 1), of which 2620
(91.9%) were term births (37 weeks or more); 373
(10.4%) ended in miscarriage; and 28 (0.8%) in still-
birth. No induced abortions were recorded in CVT
(which was conducted in a country where they are
not legal); 255 induced abortions were reported in
PATRICIA (12.1% of pregnancies in PATRICIA and
7.1% among all pregnancies). When the data file was
frozen for this analysis we had no information on the
final outcome of 93 (2.6%) pregnancies; 39 (1.1%) had
not reached20weeks’ gestation and remained at risk of
miscarriage at the last contact. The estimated rates of
miscarriage are 11.5% and 10.1% in the HPV and
hepatitis A vaccine arms, which are within the range
of international rates. 10
Result of primary test
The one sided P value for the primary permutation test
was 0.16, with the nearest vaccination as the reference
date (table 2); the more familiar two sided P value was
0.29.Most (58%) of themiscarriages occurred between
7 and 12 weeks’ gestation, consistent with published
literature.4 The permutation test result was also not sig-
nificant in groups defined by the two trials, bymaternal
age at estimated conception, by whether the pregnan-
cies were restricted by gestational age at confirmation
of pregnancy or by number of vaccinations the partici-
pant received before the estimated date of conception;
or for subsets of gestational age at miscarriage.
Rates of miscarriage for subsets of pregnancies defined by
time between nearest vaccination and conception
Figure 2 shows the counts of miscarriages and pregnan-
cies and the rates by arm according to the time between
nearest vaccination and date of estimated conception.
Table 3 summarises the underlying rates for selected
subsets of pregnancies. The difference was not
Table 3 | Rates of miscarriage by study arm for pregnancies
conceived within specified interval from nearest vaccination.
Figures are numbers (percentages) and estimates of effect
(difference in percentage, ratio)
Time interval
(days) around
vaccination HPV Hepatitis A
Estimates of
effect
−30-−1 8 (10.3) 7 (9.9) 0.4, 1.04
−30-29 32 (14.3) 18 (9.3) 5.1, 1.55
−30-59 50 (14.7) 28 (9.3) 5.4, 1.58
−30-89 66 (14.5) 41 (9.7) 4.8, 1.50
−30-849* 196 (12.2) 175 (10.7) 1.5, 1.14
0-29 24 (16.6) 11 (8.9) 7.6, 1.85
0-59 42 (16.0) 21 (9.2) 6.9, 1.75
0-89 58 (15.4) 34 (9.6) 5.8, 1.60
0-849* 188 (12.3) 168 (10.8) 1.5, 1.14
30-59 18 (15.4) 10 (9.4) 6.0, 1.63
30-89 34 (14.7) 23 (10.0) 4.7, 1.47
30-849* 164 (11.9) 157 (10.9) 0.9, 1.09
60-89 16 (13.9) 13 (10.5) 3.4, 1.33
60-849* 146 (11.5) 147 (11.0) 0.5, 1.05
90-849* 130 (11.3) 134 (11.1) 0.2, 1.02
120-849* 118 (11.2) 120 (11.0) 0.3, 1.02
180-849* 95 (10.8) 95 (10.5) 0.3, 1.03
360-849* 60 (12.6) 45 (9.8) 2.7, 1.28
*Maximum number of days between nearest vaccination and conception
date is 849.
Table 4 | Miscarriages by time between nearest vaccination and estimated conception. Figures are numbers (percentages) of miscarriages in each vaccine
group by gestation at miscarriage, with estimates of effect (difference in percentage, ratio)*
Time interval
(days) around
vaccination
0-6 weeks 7-12 weeks 13-20 weeks
HPV Hep A
Estimates of
effect HPV Hep A
Estimates of
effect HPV Hep A
Estimates of
effect
−30-0 2 (2.6) 2 (2.8) −0.3, 0.91 2 (2.6) 4 (5.6) −3.1, 0.46 4 (5.1) 1 (1.4) 3.7, 3.64
−30-29 6 (2.7) 4 (2.1) 0.6, 1.30 16 (7.2) 11 (5.7) 1.5, 1.27 9 (4.0) 3 (1.5) 2.5, 2.61
−30-59 6 (1.8) 6 (2.0) −0.2, 0.88 31 (9.1) 16 (5.3) 3.8, 1.71 12 (3.5) 5 (1.7) 1.9, 2.12
−30-89 12 (2.6) 9 (2.1) 0.5, 1.24 39 (8.6) 21 (5.0) 3.6, 1.73 14 (3.1) 10 (2.4) 0.7, 1.30
−30-849† 43 (2.7) 38 (2.3) 0.4, 1.15 108 (6.7) 107 (6.6) 0.2, 1.03 44 (2.7) 29 (1.8) 1.0, 1.54
0-29 4 (2.8) 2 (1.6) 1.1, 1.70 14 (9.7) 7 (5.7) 4.0, 1.70 5 (3.4) 2 (1.6) 1.8, 2.12
0-59 4 (1.5) 4 (1.7) −0.2, 0.87 29 (11.1) 12 (5.2) 5.8, 2.11 8 (3.1) 4 (1.7) 1.3, 1.75
0-89 10 (2.7) 7 (2.0) 0.7, 1.34 37 (9.8) 17 (4.8) 5.0, 2.04 10 (2.7) 9 (2.5) 0.1, 1.04
0-849† 41 (2.7) 36 (2.3) 0.4, 1.16 106 (6.9) 103 (6.6) 0.3, 1.05 40 (2.6) 28 (1.8) 0.8, 1.46
30-59 0 (0.0) 2 (1.9) −1.9, 0.00 15 (12.8) 5 (4.7) 8.1, 2.72 3 (2.6) 2 (1.9) 0.7, 1.36
30-89 6 (2.6) 5 (2.2) 0.4, 1.19 23 (9.9) 10 (4.3) 5.6, 2.28 5 (2.2) 7 (3.0) −0.9, 0.71
30-849† 37 (2.7) 34 (2.4) 0.3, 1.13 92 (6.7) 96 (6.7) 0.0, 1.00 35 (2.5) 26 (1.8) 0.7, 1.40
60-89 6 (5.2) 3 (2.4) 2.8, 2.16 8 (7.0) 5 (4.0) 2.9, 1.73 2 (1.7) 5 (4.0) −2.3, 0.43
60-849† 37 (2.9) 32 (2.4) 0.5, 1.22 77 (6.1) 91 (6.8) −0.7, 0.89 32 (2.5) 24 (1.8) 0.7, 1.40
90-849† 31 (2.7) 29 (2.4) 0.3, 1.12 69 (6.0) 86 (7.1) −1.1, 0.84 30 (2.6) 19 (1.6) 1.0, 1.66
120-849† 30 (2.9) 25 (2.3) 0.6, 1.25 60 (5.7) 77 (7.0) −1.3, 0.81 28 (2.7) 18 (1.6) 1.0, 1.62
180-849† 23 (2.6) 18 (2.0) 0.6, 1.32 53 (6.0) 61 (6.8) −0.7, 0.89 19 (2.2) 16 (1.8) 0.4, 1.22
360-849† 11 (2.3) 10 (2.2) 0.0, 1.06 39 (8.2) 27 (5.9) 0.0, 1.39 10 (2.1) 8 (1.7) 0.0, 1.2
*Excludes one woman with irregular menses and two women with missing date of last menstrual period.
†Maximum number of days between nearest vaccination and conception date is 849.
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significant (13.7% in HPV vaccine arm, 9.2% in hepati-
tis A vaccine arm; P=0.033; table 2) by the permutation
test for pregnancies with estimated date of conception
less than 90 days from nearest vaccination. The differ-
ence in estimated miscarriage rates between arms
among pregnancies conceived nearer vaccination
reflects higher rates in the hepatitis A arm and lower
rates in the HPV arm than in the other pregnancies.
For an estimated date of conception less than 90 days
after vaccination, most of the difference between mis-
carriage counts in the groups was for miscarriages at
7-12 weeks’ gestation (20 of the total difference of 24,
table 4). For pregnancies that began 90 days or more
after vaccination, themiscarriage rates are similar in the
two arms (counts of 130 (HPV) and 134; rates of 10.7%
and 10.5%). Results with other time scales also did not
show greater risk in the HPV arm (data not shown).
Total pregnancies and live births
The rates of total pregnancies and live birthswere simi-
lar in the two arms, with P values from the permutation
test of 0.42 for total pregnancies and 0.23 for live births
(see supplementary figs 1a and 1b in appendix 5 on
bmj.com).
DISCUSSION
We found no significant increase in miscarriage rate in
womenwho had received theCervarix vaccine against
HPVcomparedwithwomen assigned to a control arm.
We found no evidence of a decrease either in total new
pregnancies or in new pregnancies ending in live birth
in the HPV arm, and, thus, no evidence that the HPV
vaccine affected loss of undetected pregnancies.
Among our subgroup analyses, we found a non-signif-
icant imbalance in estimated miscarriage rates for
pregnancies conceived within three months after the
nearest vaccination, the time frame with the highest
prior probability of an effect. We found no sign of a
detrimental effect of HPV vaccination on miscarriage
rates for pregnancies conceived beyond three months
after vaccination, even thoughpower to detect an effect
with a relative risk of about 2 during this time period
was substantial.
Strengths and weaknesses
Despite the reassurance from our overall results and
from studies of other vaccines, we looked carefully
for signs of increased risk of miscarriage because
even a small effect could cause a large number of mis-
carriages among themillions of sexually active women
worldwide whom we expect to receive the HPV vac-
cine. We used the permutation test to maintain power
to find an effect across a range of subsets of pregnancies
possibly at increased risk, while strictly controlling the
chance of a false positive result that could lead to over-
interpretation of an apparent effect found a posteriori
in some subsets of pregnancies.
Theabsenceof a vaccine effect is consistentwithother
information about risk of miscarriage from vaccination
with Cervarix and Gardasil or other vaccines before or
during pregnancy. The May 2008 update of guidelines
from the Advisory Committee on Immunization Prac-
tices (ACIP) of theCenters forDiseaseControl andPre-
vention states that risk from vaccinating pregnant
women is “primarily theoretical,” and that no evidence
has shown a risk with vaccines that are not live.11 ACIP
guidelines for Gardasil, which uses the same type of
antigen as Cervarix but with a different adjuvant, do
not recommend use during pregnancy, though they
note that the limited data on vaccination during preg-
nancy do not show a causal association with adverse
outcomes or adverse events in the developing fetus.12
The power of our study to detect amoderate effect of
the vaccine in subsets of pregnancies, the absence of
established effects of other vaccines on miscarriage,
and the low prior probability that Cervarix has an
effect on miscarriage combined with the limited statis-
tical evidence of effect lead us to conclude that the
HPV vaccine probably does not cause miscarriage.
The observed variation in the differences between
rates ofmiscarriage between arms in the subset of preg-
nancies conceived closer to vaccination is consistent
with a small effect of vaccination or statistical noise.
The similarity of miscarriage rates in the two arms for
conceptions that began beyond threemonths after vac-
cination provides some reassurance that there is no
long term effect of the vaccine.
Nonetheless, we cannot completely rule out the pos-
sibility of an increased risk among pregnancies con-
ceived within three months of vaccination. It is
unlikely that postmarketing surveillance will find
small but important effects of vaccination on miscar-
riage because of the difficulties of ascertaining miscar-
riages in comparable unvaccinated women and
determining timing of last menstrual period in vacci-
nated women, which is needed to investigate whether
any effect is restricted to pregnancies conceived near
vaccination. We recommend further analyses of data
on miscarriage from randomised controlled trials to
help to clarify further whether vaccines have any effect
on miscarriage: pooling reported and as yet unre-
ported data on both vaccines with the VLP antigen—
that is, Cervarix and Gardasil—and pooling all data
from Cervarix and other GSK vaccines containing
the same novel adjuvant as Cervarix.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Women of reproductive age are a target for vaccines against human papillomavirus (HPV)
Generally, non-live vaccines administered around the time of conception or during pregnancy
do not increase the risk of miscarriage
Evidence about the effect of the antigen and adjuvant used in Cervarix on the risk of
miscarriage is limited
WHAT THIS STUDY ADDS
There is no overall effect of vaccination with Cervarix on risk of miscarriage
A small increase seen in risk of miscarriage in the subgroup of pregnancies conceived within
three months of vaccination is compatible with chance, but does raise concern for a vaccine
that is likely to be administered to millions of women of reproductive age
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